Cell And Gene Therapy Market Growth, Drivers Report 2026 to 2035

How Has The Size And Value Of The Cell and Gene Therapy Market Changed During The 2026–2030 Period?
The cell and gene therapy market size has grown exponentially in recent years. It will grow from $21.33 billion in 2025 to $26.21 billion in 2026 at a compound annual growth rate (CAGR) of 22.9%. The growth in the historic period can be attributed to limited availability of cell and gene therapies, reliance on conventional treatment modalities, high cost of early-generation therapies, growing incidence of oncology and neurological disorders, lack of specialized treatment centers.

The cell and gene therapy market size is expected to see exponential growth in the next few years. It will grow to $60.58 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to development of advanced car-t and genome editing therapies, expansion of clinical trials and research programs, increasing adoption of personalized medicine, rising government support and funding for rare disease treatments, integration of digital platforms for therapy monitoring and patient management. Major trends in the forecast period include increasing adoption of car-t and stem cell therapies, rising investment in gene therapy for oncology and rare diseases, growth in personalized and targeted cell-based treatments, expansion of hospital and ambulatory surgical centers offering advanced therapies, integration of genome editing and viral vector-based technologies in clinical practice.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What Drivers Are Contributing To The Expansion Trajectory Of The Cell and Gene Therapy Market?
A growing number of ongoing clinical trials is expected to propel the growth of the cell and gene therapy market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. Clinical trials play a vital role in the development and advancement of cell and gene therapy. They provide a safe and controlled environment to test new therapies and collect data on their safety and efficacy. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, a growing number of ongoing clinical trials is driving the growth of the cell and gene therapy market.

Which Primary Segments Are Included In The Detailed Analysis Of The Cell and Gene Therapy Market?
The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:
1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy


What Current Industry Trends Are Affecting The Performance Of The Cell and Gene Therapy Market?
Major companies operating in the cell and gene therapy market are increasing their focus on introducing agnostic systems to gain a competitive edge in the market. Agnostic systems refer to systems that are integrated with a variety of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub, a new platform-agnostic system that aims to improve connectivity across the cell and gene therapy (CGT) treatment journey to enable an enhanced patient and provider experience. The hub is powered by the company's customer relationship management system and is designed to speed up the benefits investigation process, give a real-time view of therapy development and transportation status, and assist in coordinating patient support.

Which Major Corporations Play A Crucial Role In The Cell and Gene Therapy Market Landscape?
Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Get Your In-Depth Cell and Gene Therapy Market Report Now:
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Which Regions Demonstrate The Highest Growth Momentum In The Cell and Gene Therapy Market?
North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company